Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status

NCT01228734 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01228734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01228734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 3
Overall status
Completed
Start date
September 9, 2010
Completion date
January 31, 2018
Enrollment
553 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer